

## LABORATORY-DEVELOPED TESTING: TECHNOLOGIES AND MARKETS



HLC179A  
January 2015

Todd Graham  
*Project Analyst*

ISBN: 1-62296-021-1



**BCC Research**  
49 Walnut Park, Building 2  
Wellesley, MA 02481 USA  
866-285-7215 (toll-free within the USA),  
or (+1) 781-489-7301  
[www.bccresearch.com](http://www.bccresearch.com)  
[information@bccresearch.com](mailto:information@bccresearch.com)

**TABLE OF CONTENTS**

<b>TOPIC</b>	<b>PAGE NO.</b>
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR DOING THE STUDY	2
SCOPE OF REPORT	2
INTENDED AUDIENCE	3
INFORMATION SOURCES	3
ANALYST'S CREDENTIALS	3
RELATED BCC RESEARCH REPORTS	3
BCC RESEARCH WEBSITE	4
DISCLAIMER	4
CHAPTER 2 SUMMARY	6
<i>SUMMARY TABLE MARKET FOR U.S. LABORATORY-DEVELOPED TESTS, THROUGH 2019 (\$ MILLIONS)</i>	6
<i>SUMMARY FIGURE MARKET FOR U.S. LABORATORY-DEVELOPED TESTS, 2012-2019 (\$ MILLIONS)</i>	6
KEY TRENDS	7
THE RISE OF FDA REGULATION	7
GENOMIC RAMP-UP	7
DECLINE OF THE ACADEMIC MEDICAL CENTER	7
EVOLUTION OF THE LABORATORY-DEVELOPED TEST (LDT)	7
MOLECULAR DIAGNOSTICS EXPLOSION	7
SHIFTS TOWARDS LICENSING AND STARTUP INVESTMENT	8
SLOW DECLINE OF SEROLOGY	8
CHAPTER 3 OVERVIEW: DESCRIPTION OF LABORATORY-DEVELOPED TESTS	10
LIFE CYCLE OF CLINICAL DIAGNOSTIC TESTS	10
<i>TABLE 1 LIFE CYCLE OF CLINICAL DIAGNOSTIC TESTS</i>	12
WHY USE AN LDT	12
COMMON TECHNOLOGIES USED	13
POLYMERASE CHAIN REACTION (PCR)	13
How PCR Works in an LDT	14
NEXT-GENERATION SEQUENCING	15
How NGS Works in LDTs	16
Sequencing by Synthesis	16
SOLiD Sequencing	17
Semiconductor Sequencing	17
OTHER MOLECULAR TECHNOLOGIES	18
MASS SPECTROMETRY	18
How Mass Spectrophotometry Works in LDTs	19
HPLC-MS	19
MALDI-TOF	20
IMMUNOASSAYS	20
How an Immunoassay Works in an LDT	21
CLINICAL INDICATIONS	23
ONCOLOGY	23

<b>TOPIC</b>	<b>PAGE NO.</b>
INFECTIOUS DISEASE	23
RARE DISEASES	24
MATERNITY	24
CHRONIC DISEASE	24
DIFFERENCES BETWEEN LDTS AND FDA APPROVED TESTS	25
CHAPTER 4 USES OF LABORATORY-DEVELOPED TESTS	28
<i>TABLE 2 USES OF LABORATORY-DEVELOPED TESTS</i>	28
ESOTERIC TESTING	28
ANATOMIC PATHOLOGY	29
PUBLIC HEALTH	30
NEW TECHNOLOGY	30
MOLECULAR DIAGNOSTICS	31
MASS SPECTROPHOTOMETRY	31
GENOMICS AND NEXT-GENERATION SEQUENCING	32
CHAPTER 5 SEGMENTS	34
CLINICAL DIAGNOSTICS	34
<i>TABLE 3 SEGMENTS OF THE CLINICAL DIAGNOSTIC INDUSTRY</i>	34
SPECIALTY LABORATORIES	35
REFERENCE LABORATORIES	35
ACADEMIC MEDICAL CENTERS	36
ANALYTE-SPECIFIC REAGENTS	36
<i>TABLE 4 SUMMARY OF LABORATORY-DEVELOPED TEST MARKET SEGMENTS</i>	37
CHAPTER 6 LABORATORY-DEVELOPED CLINICAL ASSAYS	39
<i>TABLE 5 U.S. MARKET FOR LABORATORY-DEVELOPED CLINICAL ASSAYS, THROUGH 2019 (\$ MILLIONS)</i>	39
ANATOMIC PATHOLOGY	40
<i>TABLE 6 U.S. MARKET FOR ANATOMIC PATHOLOGY LABORATORY-DEVELOPED TESTS, THROUGH 2019 (\$ MILLIONS)</i>	40
GENOMIC TESTING	41
<i>TABLE 7 U.S. MARKET FOR GENOMIC LABORATORY-DEVELOPED TESTS, THROUGH 2019 (\$ MILLIONS)</i>	41
MASS SPECTROPHOTOMETRY	42
<i>TABLE 8 U.S. MARKET FOR MASS SPECTROPHOTOMETRY LABORATORY-DEVELOPED TESTS, THROUGH 2019 (\$ MILLIONS)</i>	42
SEROLOGY	43
<i>TABLE 9 U.S. MARKET FOR SEROLOGY LABORATORY-DEVELOPED TESTS, THROUGH 2019 (\$ MILLIONS)</i>	43
MOLECULAR DIAGNOSTICS	44
<i>TABLE 10 U.S. MARKET FOR MOLECULAR DIAGNOSTICS LABORATORY-DEVELOPED TESTS, THROUGH 2019 (\$ MILLIONS)</i>	44
CHAPTER 7 ANALYTE-SPECIFIC REAGENTS	47
ANALYTE-SPECIFIC REAGENT MARKET	47
<i>TABLE 11 U.S. MARKET FOR ANALYTE-SPECIFIC REAGENTS FOR LABORATORY-DEVELOPED TESTS, THROUGH 2019 (\$ MILLIONS)</i>	47
CONTRACT MANUFACTURERS	48

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 12 U.S. MARKET FOR ANALYTE-SPECIFIC REAGENTS FROM CONTRACT MANUFACTURERS FOR LABORATORY-DEVELOPED TESTS, THROUGH 2019 (\$ MILLIONS)</i>	48
SPECIALTY MANUFACTURERS	49
<i>TABLE 13 U.S. MARKET FOR ANALYTE-SPECIFIC REAGENTS FROM SPECIALTY MANUFACTURERS FOR LABORATORY-DEVELOPED TESTS, THROUGH 2019 (\$ MILLIONS)</i>	49
CHAPTER 8 TECHNOLOGY AND PATENTS	51
AUTISM ASSOCIATED GENETIC MARKERS-LINEAGEN	51
SUMMARY OF THE PATENT	51
IMPLICATIONS OF THE PATENT	52
LINEAGEN	52
COMPETITIVE ANALYSIS	53
DIAGNOSTIC PROCESSES THAT FACTOR EXPERIMENTAL CONDITIONS-SEQUENOM	53
SUMMARY OF THE PATENT	53
IMPLICATIONS OF THE PATENT	54
SEQUENOM	54
COMPETITIVE ANALYSIS	55
METHODS FOR IMPROVING INFLAMMATORY BOWEL DISEASE DIAGNOSIS-NESTLE/PROMETHEUS DIAGNOSTICS	55
SUMMARY OF THE PATENT	55
IMPLICATIONS OF THE PATENT	56
PROMETHEUS DIAGNOSTICS	56
COMPETITIVE ANALYSIS	57
METHODS AND COMPOSITIONS FOR UNIVERSAL DETECTION OF NUCLEIC ACIDS-UNITAQ BIO	57
SUMMARY OF THE PATENT	57
IMPLICATIONS OF THE PATENT	57
UNITAQ BIO	58
COMPETITIVE ANALYSIS	58
GENETIC POLYMORPHISMS ASSOCIATED WITH ALZHEIMER'S DISEASE, METHODS OF DETECTION AND USES THEREOF-CELERA/ QUEST DIAGNOSTICS	58
SUMMARY OF THE PATENT	58
IMPLICATIONS OF THE PATENT	59
QUEST DIAGNOSTICS	59
COMPETITIVE ANALYSIS	60
MATERIALS AND METHODS FOR DETERMINING DIAGNOSIS AND PROGNOSIS OF PROSTATE CANCER-THE REGENTS OF THE UNIVERSITY OF CALIFORNIA/PROVERI	60
SUMMARY OF THE PATENT	60
IMPLICATIONS OF THE PATENT	60
PROVERI	61
COMPETITIVE ANALYSIS	61
METHOD AND KIT FOR CHARACTERIZING MICROORGANISMS-FRY LABORATORIES	62
SUMMARY OF THE PATENT	62
IMPLICATIONS OF THE PATENT	62
FRY LABORATORIES	63

<b>TOPIC</b>	<b>PAGE NO.</b>
COMPETITIVE ANALYSIS	63
BIOMARKERS FOR MONITORING TREATMENT OF NEUROPSYCHIATRIC DISEASES-RIDGE DIAGNOSTICS	63
SUMMARY OF THE PATENT	63
IMPLICATIONS OF THE PATENT	64
RIDGE DIAGNOSTICS	64
COMPETITIVE ANALYSIS	65
<i>TABLE 14 PATENT APPLICATIONS FOR LABORATORY-DEVELOPED TESTING</i>	66
CHAPTER 9 LABORATORY-DEVELOPED TEST R&D	68
RAPID DETECTION OF INFECTIOUS DISEASE	68
APPLICATION OF GENOMIC LDTS	68
USE OF CIRCULATING TUMOR CELLS IN DIAGNOSTICS	69
CHAPTER 10 INDUSTRY STRUCTURE	72
REAGENT MANUFACTURERS	72
REFERENCE LABORATORIES	72
ACADEMIC MEDICAL CENTERS	72
SPECIALTY LABORATORIES	73
REGULATORY	73
TRENDS IN PRICE AND PERFORMANCE	73
INDUSTRIAL CHANGES	73
CHAPTER 11 GOVERNMENT REGULATIONS	75
CLINICAL DIAGNOSTICS	75
CLIA VS. FDA	76
<i>TABLE 15 DIVISION OF LABORATORY SERVICE CENTERS FOR MEDICARE AND MEDICAID SERVICES, LABORATORIES BY TYPE OF FACILITY (EXEMPT/NON-EXEMPT COMBINED), CLIA UPDATE, THROUGH JUNE 2014</i>	77
IMPACT OF THE FDA'S GUIDANCE ON LDTS	78
SUMMARY OF FDA'S DRAFT GUIDANCE	78
IMPLICATIONS	79
CASE STUDY: GOOGLE'S 23ANDME	80
REGULATIONS OUTSIDE OF THE UNITED STATES	81
REGULATIONS WITHIN ASIA	81
AUSTRALIAN LDT REGULATIONS	81
STATUS OF LDTS WITHIN EUROPE	82
HEALTH CANADA AND LDTS	83
CHAPTER 12 INDUSTRY ISSUES	85
INDUSTRY ANALYSIS	85
FDA VERSUS THE LDT INDUSTRY	85
FDA's Perspective	85
LDT Industry's Perspective	85
Points of Contention	86
Potential Paths Forward	86
Evolution of Genomic Tests	87
TWO-TIER BUSINESS	88

<b>TOPIC</b>	<b>PAGE NO.</b>
REIMBURSEMENT AND PAYER MARKETS	88
CODING A TEST	89
VALUING THE LDT	89
POTENTIAL SOLUTIONS	90
INDUSTRY RECOMMENDATIONS	90
INVEST IN INFORMATION TECHNOLOGY PARTICULARLY DATABASE MANAGEMENT	90
ENCOURAGE TIE-INS WITH EXISTING ELECTRONIC HEALTH RECORD SYSTEMS	91
SUPPORT EFFORTS TO REGULATE LDTS FOR ROUTINE ANALYTES	91
SELL OFF INTELLECTUAL PROPERTY	92
ENCOURAGE ONE-STOP SHOPPING WITHIN SPECIALTIES FOR LABORATORY-DEVELOPED TESTS	92
CLINICAL LABORATORY IMPROVEMENT AMENDMENTS (CLIA): STATE SURVEY AGENCY CONTACTS	93
CHAPTER 13 COMPANY PROFILES	104
23ANDME	104
ACCESS GENETICS	104
ARUP LABORATORIES	104
ASURAGEN	105
BD	105
BIOREFERENCE	106
BIOTHERANOSTICS	106
CYTOCELL	107
EMPIRE GENOMICS	107
ENZO BIOCHEM	107
EUROFINS	108
FRY LABORATORIES	108
GENECENTRIC DIAGNOSTICS	108
GENOMIC HEALTH	109
IDT	109
ILLUMINA	109
LABCORP	110
LUMINEX	110
MERCK KGAA	110
MOLECULARHEALTH	111
MYRIAD GENETICS	111
NEOGENOMICS	111
OLIGOS ETC.	112
PROVERI INC.	112
QUEST DIAGNOSTICS	112
RIDGE DIAGNOSTICS	113
ROSETTA GENOMICS	113
SELAH GENOMICS	114
SEQUENOM	114
SIEMENS	115
SIGNAL GENETICS	115

<b>TOPIC</b>	<b>PAGE NO.</b>
THERMO FISHER	115
UNITAQ BIO	116
VENTANA MEDICAL SYSTEMS INC.	116

**LIST OF TABLES**

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
SUMMARY TABLE MARKET FOR U.S. LABORATORY-DEVELOPED TESTS, THROUGH 2019 (\$ MILLIONS)	6
TABLE 1 LIFE CYCLE OF CLINICAL DIAGNOSTIC TESTS	12
TABLE 2 USES OF LABORATORY-DEVELOPED TESTS	28
TABLE 3 SEGMENTS OF THE CLINICAL DIAGNOSTIC INDUSTRY	34
TABLE 4 SUMMARY OF LABORATORY-DEVELOPED TEST MARKET SEGMENTS	37
TABLE 5 U.S. MARKET FOR LABORATORY-DEVELOPED CLINICAL ASSAYS, THROUGH 2019 (\$ MILLIONS)	39
TABLE 6 U.S. MARKET FOR ANATOMIC PATHOLOGY LABORATORY-DEVELOPED TESTS, THROUGH 2019 (\$ MILLIONS)	40
TABLE 7 U.S. MARKET FOR GENOMIC LABORATORY-DEVELOPED TESTS, THROUGH 2019 (\$ MILLIONS)	41
TABLE 8 U.S. MARKET FOR MASS SPECTROPHOTOMETRY LABORATORY-DEVELOPED TESTS, THROUGH 2019 (\$ MILLIONS)	42
TABLE 9 U.S. MARKET FOR SEROLOGY LABORATORY-DEVELOPED TESTS, THROUGH 2019 (\$ MILLIONS)	43
TABLE 10 U.S. MARKET FOR MOLECULAR DIAGNOSTICS LABORATORY-DEVELOPED TESTS, THROUGH 2019 (\$ MILLIONS)	44
TABLE 11 U.S. MARKET FOR ANALYTE-SPECIFIC REAGENTS FOR LABORATORY-DEVELOPED TESTS, THROUGH 2019 (\$ MILLIONS)	47
TABLE 12 U.S. MARKET FOR ANALYTE-SPECIFIC REAGENTS FROM CONTRACT MANUFACTURERS FOR LABORATORY-DEVELOPED TESTS, THROUGH 2019 (\$ MILLIONS)	48
TABLE 13 U.S. MARKET FOR ANALYTE-SPECIFIC REAGENTS FROM SPECIALTY MANUFACTURERS FOR LABORATORY-DEVELOPED TESTS, THROUGH 2019 (\$ MILLIONS)	49
TABLE 14 PATENT APPLICATIONS FOR LABORATORY-DEVELOPED TESTING	66
TABLE 15 DIVISION OF LABORATORY SERVICE CENTERS FOR MEDICARE AND MEDICAID SERVICES, LABORATORIES BY TYPE OF FACILITY (EXEMPT/NON-EXEMPT COMBINED), CLIA UPDATE, THROUGH JUNE 2014	77



**LIST OF FIGURES**

<b>FIGURE TITLE</b>	<b>PAGE NO.</b>
SUMMARY FIGURE MARKET FOR U.S. LABORATORY-DEVELOPED TESTS, 2012-2019 (\$ MILLIONS)	6